Get started
Author

Pearl Wang

Observed name: Wang, Pearl
Institution: EVERSANA (Canada)
OpenAlex ID: A5039728929
From Knowledge-based to Competency-based Computing Education: Future Directions
2020 · Alison Clear, Tony Clear, et al. · IEEE Frontiers in Education Conference (FIE) · 39
Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus
2022 · Ian N Bruce, Sarowar Golam, et al. · Journal of Comparative Effectiveness Research · 32
A Novel Self-Paced Model for Teaching Programming
2017 · Jeff Offutt, Paul Ammann, et al. · ACM Conference on Learning @ Scale (L@S) · 16
Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma
2025 · Loretta J. Nastoupil, Ashley Bonner, et al. · Experimental Hematology and Oncology · 14
Matching-Adjusted Indirect Comparison (MAIC) of Efficacy and Safety of Lisocabtagene Maraleucel (liso-cel) and Mosunetuzumab for the Treatment (Tx) of Third Line or Later (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
2023 · Loretta J. Nastoupil, Ashley Bonner, et al. · Blood · 10
Matching-adjusted indirect comparison of lisocabtagene maraleucel versus axicabtagene ciloleucel for second-line treatment of patients with early relapsed or refractory large B-cell lymphoma
2025 · Jeremy S. Abramson, Manali Kamdar, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 5
PDF
Chapter 14. Applications and protocols
1981 · Stephen R. Kimbleton, Pearl Wang, et al. · Lecture notes in computer science · 5
Health care resource utilization in 3L + patients with chronic phase chronic myeloid leukemia receiving asciminib or bosutinib
2023 · Jorge E. Cortes, Delphine Rea, et al. · Journal of Medical Economics · 4
PDF
Matching-Adjusted Indirect Comparison (MAIC) of Efficacy and Safety Outcomes for Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for the Treatment of Third-Line or Later (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
2024 · Alexander P. Boardman, Juan Luis Reguera, et al. · Blood · 3
Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (Liso-cel) Versus Axicabtagene Ciloleucel (Axi-cel) for Second-Line (2L) Treatment of Patients (Pt) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL)
2022 · Jeremy S. Abramson, Manali Kamdar, et al. · Blood · 3
Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Second-Line (2L) Treatment of Patients (pts) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL): Update with 34 Months of Liso-Cel Follow-up
2024 · Jeremy S. Abramson, Manali Kamdar, et al. · Blood · 2
PDF
Postmarketing safety profile of chimeric antigen receptor (CAR) T cell therapies in diffuse large B-cell lymphoma (DLBCL): Analysis of real-world (RW) AE reporting from the FDA Adverse Event Reporting System (FAERS).
2025 · Matthew Alexander Lunning, Marcela Valderrama Maus, et al. · Journal of Clinical Oncology · 1
PDF
Matching-adjusted indirect comparison (MAIC) of lisocabtagene maraleucel (liso-cel) versus axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) for treatment of third-line or later (3L+) R/R follicular lymphoma (FL): Update with 24 months of liso-cel follow-up (FU).
2025 · Alexander Paul Boardman, Juan Luis Reguera, et al. · Journal of Clinical Oncology · 1
Letter in reply: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus
2022 · Ian N Bruce, Sarowar Golam, et al. · Journal of Comparative Effectiveness Research · 1
Safety Profile of Chimeric Antigen Receptor T-cell Therapies in Diffuse Large B-cell Lymphoma: An Analysis of Real-World Adverse Event Reporting From the FDA Adverse Event Reporting System
2026 · Magdi Elsallab, Matthew Lunning, et al. · Mayo Clinic Proceedings Innovations Quality & Outcomes
Indirect Treatment Comparisons of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in Third-Line or Later Relapsed or Refractory Follicular Lymphoma
2026 · Alexander P. Boardman, Juan Luis Reguera Ortega, et al. · Advances in Therapy
CO58 Comparative Efficacy of Iptacopan Monotherapy vs. Danicopan Add-on to C5i in Paroxysmal Nocturnal Hemoglobinuria (PNH) Results From an Indirect Treatment Comparison (ITC)
2025 · Phillip Scheinberg, Austin Kulasekararaj, et al. · Value in Health
Infections in Patients (Pts) with Multiple Myeloma (Mm) Treated with BCMA-Directed CAR T Cell Therapies and Bispecific Antibodies: Analysis of the FDA Adverse Event Reporting System (FAERS)
2025 · Surbhi Sidana, Krina Patel, et al. · Clinical Lymphoma Myeloma & Leukemia
Additional file 1 of Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma
2025 · Nastoupil, Loretta J., Bonner, Ashley, et al. · Figshare
Matching-Adjusted Indirect Comparison of Efficacy and Safety Outcomes for Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel for the Treatment of Third-Line or Later Relapsed or Refractory Follicular Lymphoma
2024 · Boardman, Alexander Paul, Reguera-Ortega, Juan Luis, et al. · DIGITAL.CSIC (Spanish National Research Council (CSIC))
Teaching a creativity-based skill through self-pacing
2016 · Kinga Dobolyi, Paul Amman, et al. · Innovations in Teaching & Learning Conference Proceedings
PDF
Works count: 21
Citation count: 136
H-index: 5
I10-index: 5
Year
Topic
Type